Celecoxib (SC 58635) - Moligand™, 10mM in DMSO , Cyclooxygenase-2 inhibitor, CAS No.169590-42-5, Cyclooxygenase-2 inhibitor

CAS: 169590-42-5 Cat. No.: C408187 Molecular Weight: 381.37 EC Number: 685-962-5
AVAILABLE TO ORDER
GRADE & PURITY Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Synonyms
4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
1ml
C408187-1ml
1
$79.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 38 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

Information

Celecoxib (SC 58635) is a selectiveCOX-2inhibitor withIC50of 40 nM in Sf9 cells.
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively.

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days).
Cell Data

cell lines:

Concentrations:0-75 μM

Incubation Time:48 hours

Powder Purity:≥99%

Specifications

Synonyms
4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
Specifications & Purity
Moligand™, 10mM in DMSO
Biochemical and Physiological Mechanisms
Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Grade
Moligand™
Action Type
INHIBITOR
Mechanism of action
Cyclooxygenase-2 inhibitor
Product Properties
ALogP3.4
Names and Identifiers
Isomeric SMILES CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
WGK Germany 3
RTECS DB2944937
Alternate CAS 169590-42-5
NSC Number 719627
MeSH Entry Terms 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide;Celebrex;celecoxib;SC 58635;SC-58635;SC58635
Molecular Weight 381.37
Reaxy-Rn 7662430
Reaxys-RN_link_address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=7662430&ln=

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Associated Targets(Human)
CYP2D6 Tclin Cytochrome P450 2D6 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
MT-CO2 Tchem Cytochrome c oxidase subunit 2 (3 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA5A Tclin Carbonic anhydrase 5A, mitochondrial (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PTGES Tchem Prostaglandin E synthase (3 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HDAC6 Tclin Histone deacetylase 6 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PTGS1 Tclin Prostaglandin G/H synthase 1 (10 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PTGS2 Tclin Prostaglandin G/H synthase 2 (172 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA5B Tclin Carbonic anhydrase 5B, mitochondrial (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA6 Tclin Carbonic anhydrase 6 (3 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA13 Tclin Carbonic anhydrase 13 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA2 Tclin Carbonic anhydrase 2 (48 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA4 Tclin Carbonic anhydrase 4 (4 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA12 Tclin Carbonic anhydrase 12 (8 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA14 Tclin Carbonic anhydrase 14 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CA9 Tclin Carbonic anhydrase 9 (12 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
SolubilitySolubility (25°C) In vitro DMSO: 67 mg/mL (201.61 mM); Ethanol: -1 mg/mL  
Melt Point(°C)163 °C
Documents & Articles
Citations of This Product
References
1. Xiaoxiang Cheng, Zhe Xu, Xinsheng Luo, Yi Chai, Jiajian Xing, Xinyu Zhang, Jingtao Xu.  (2025)  Self-limiting interfacial synthesis of inorganic thin films for high-performance organic solvent nanofiltration in pharmaceutical applications.  SEPARATION AND PURIFICATION TECHNOLOGY,      [PMID:] [10.1016/j.seppur.2025.134261]
2. Xiaoliang Deng, Xianquan Feng, Xiaohui Tang, Zhihui Zheng, Da Zheng, Enqin Zheng, Lingjun Zeng, Shiying Xu, Boxin Chen, Qian Zhang, Zhihong Liu, Hongtao Song.  (2025)  Self-Delivery Nanotherapeutics for Tumor Low-Temperature Photothermal Immunotherapy through Cascade Heat Shock Protein and Inflammation Inhibition.  ACS Applied Materials & Interfaces,      [PMID:40735962] [10.1021/acsami.5c10905]
3. Mingyue Yin, Xinyi Xiao, Yang Xiao, Jingyan Zhou, Shuxian Liu, Xue Jiang, Xiaomin Han, Tao Zhuang, Yin Chen.  (2025)  Discovery of two new co-drugs of celecoxib and gabapentinoids for treating chemotherapy-induced peripheral neuropathy.  EUROPEAN JOURNAL OF PHARMACOLOGY,      [PMID:40618982] [10.1016/j.ejphar.2025.177919]
4. Mengyang Cai, Pengpeng Yang, Jinqiu Fu, Guiyu Chen, Keke Zhang.  (2025)  Insights into the Effect of Nanoconfinement Surface Chemistry on Celecoxib Aggregation and Dissolution by 19F NMR Spectroscopy.  CRYSTAL GROWTH & DESIGN,      [PMID:] [10.1021/acs.cgd.5c00656]
5. Hong Tang, Qi Dai, Ziyan Zhao, Weiye Ge, Danlei Li, Zelin Chang, Penglai Pi, Jia Li, Zheng Sun.  (2025)  Melatonin Synergises the Chemotherapeutic Effect of Temozolomide in Glioblastoma by Suppressing NF-κB/COX-2 Signalling Pathways.  JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,  29  (15): (e70778).  [PMID:40804775] [10.1111/jcmm.70778]
6. Shiying Xu, Lina Wu, Boxin Chen, Xiaoliang Deng, Zhihui Zheng, Fei Wu, Lingjun Zeng, Changqing Zheng, Xiaomu Hu, Aiwen Huang, Xin Zhou, Xianquan Feng, Zhihong Liu.  (2025)  A self-delivery albumin nanomedicine amplified photodynamic therapy against esophageal cancer through COX-2/PGE2 interruption and regulation of mitochondrial respiratory.  International Journal of Pharmaceutics-X,      [PMID:41089759] [10.1016/j.ijpx.2025.100407]
7. Xiangyun Tan, Yuan Yang, Junjie Hu, Yan Meng, Liang Chen, Guohua Zheng, Han Xiao, Zhenpeng Qiu.  (2025)  Celecoxib blocks AKT/mTOR in AKT/YapS127A-driven intrahepatic cholangiocarcinoma, activating p21/p27 for cycle arrest and suppressing Mcl-1 for apoptosis.  CHEMICO-BIOLOGICAL INTERACTIONS,      [PMID:40930397] [10.1016/j.cbi.2025.111737]
8. Yongjing Cao, Juan Li, Qiangwei Liang, Jiayu Yang, Xiaojie Zhang, Juntao Zhang, Min An, Jiawei Bi, Yanhua Liu.  (2023)  Tumor Microenvironment Sequential Drug/Gene Delivery Nanosystem for Realizing Multistage Boosting of Cancer–Immunity Cycle on Cancer Immunotherapy.  ACS Applied Materials & Interfaces,      [PMID:37963093] [10.1021/acsami.3c11394]
9. Xiaoyu Han, Fan Wang, Jieliang Shen, Shuyu Chen, Pengcheng Xiao, Ying Zhu, Weiwei Yi, Zhengyu Zhao, Zhengwei Cai, Wenguo Cui, Dingqun Bai.  (2023)  Ultrasound Nanobubble Coupling Agent for Effective Noninvasive Deep-Layer Drug Delivery.  ADVANCED MATERIALS,      [PMID:37851922] [10.1002/adma.202306993]
10. Shouchao Xu, Jiehong Yang, Haitong Wan, Li Yu, Yu He.  (2023)  Combination of Radix Astragali and Safflower Promotes Angiogenesis in Rats with Ischemic Stroke via Silencing PTGS2.  INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,  24  (3): (2126).  [PMID:36768450] [10.3390/ijms24032126]
11. Chen An, Cai Peishan, Luo Minqian, Guo Minshan, Cai Ting.  (2022)  Melt Crystallization of Celecoxib-Carbamazepine Cocrystals with the Synchronized Release of Drugs.  PHARMACEUTICAL RESEARCH,  40  (2): (567-577).  [PMID:36348133] [10.1007/s11095-022-03427-3]
12. Xin Zhao, Lingyu Li, Shuang Li, Jinyu Liu, Hongya Wang, Yulin Lin, Dayong Cai.  (2022)  Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3.  EUROPEAN JOURNAL OF PHARMACOLOGY,      [PMID:35738453] [10.1016/j.ejphar.2022.175115]
13. Cong Zhang, Yuzhen Lu, Yingying Song, Liang Chen, Junjie Hu, Yan Meng, Xin Chen, Shan Li, Guohua Zheng, Zhenpeng Qiu.  (2022)  Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway.  JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,  26  (14): (3995-4006).  [PMID:35713152] [10.1111/jcmm.17435]
14. Jialiang Lin, Junchao Huang, Jiang Wu, Bo Tang, Congbin Li, Haijun Xiao.  (2022)  Poly(lactic acid-co-glycolic acid)-based celecoxib extended-release microspheres for the local treatment of traumatic heterotopic ossification.  JOURNAL OF BIOMATERIALS APPLICATIONS,      [PMID:35043696] [10.1177/08853282211056937]
15. Changyou Yu, Menghui Yao, Yiming Ma, Yanbo Liu, Shilin Guo, Shijie Xu, Sohrab Rohani, Mingyang Chen, Junbo Gong.  (2021)  Design of the spherical agglomerate size in crystallization by developing a two-step bridging mechanism and the model.  AICHE JOURNAL,  68  (2): (e17526).  [PMID:] [10.1002/aic.17526]
16. Muhammad Asim Farooq, Amna Jabeen, Bo Wang.  (2021)  Formulation, optimization, and characterization of whey protein isolate nanocrystals for celecoxib delivery.  JOURNAL OF MICROENCAPSULATION,      [PMID:33896352] [10.1080/02652048.2021.1915398]
17. Wei Gu, Qinfu Zhao, Ye He, Shengyu Wang, Yuanqi Yang, Yian Li, Shuaipeng Feng, Siling Wang.  (2024)  Different mesoporous carbon carriers for the improvement of solubility and physical stability of poorly soluble drugs.  COLLOIDS AND SURFACES B-BIOINTERFACES,      [PMID:39705828] [10.1016/j.colsurfb.2024.114436]
18. Zixinying Han, Chenxu Liu, Mingrui Li, Mengyan Deng, Ying Ding, Yunchao Li, Meidan Huo, Haiwei Xu, Hailing Qiao, Na Gao.  (2024)  Discovery of CYP2E1 as a novel target in rheumatoid arthritis and validation by a new specific CYP2E1 inhibitor.  BIOCHEMICAL PHARMACOLOGY,      [PMID:39173843] [10.1016/j.bcp.2024.116501]
19. Zhang Xiaojie, Liang Qiangwei, Cao Yongjin, Yang Ting, An Min, Liu Zihan, Yang Jiayu, Liu Yanhua.  (2024)  Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.  JOURNAL OF NANOBIOTECHNOLOGY,  22  (1): (1-19).  [PMID:38849938] [10.1186/s12951-024-02598-y]
20. Minqian Luo, An Chen, Chengbin Huang, Minshan Guo, Ting Cai.  (2024)  Effects of Polymers on Cocrystal Growth in a Drug–Drug Coamorphous System: Relations between Glass-to-Crystal Growth and Surface-Enhanced Crystal Growth.  MOLECULAR PHARMACEUTICS,      [PMID:38818946] [10.1021/acs.molpharmaceut.4c00315]
21. Huang Lin, Wang Wantao, Liu Lei, Ma Wenzheng, Fan Jinghao, Zhou Dan, Zhao Lei, Zheng Zhaomin, Liu Hongmei, Wu Decheng.  (2025)  Injectable chitosan microspheres resisting inflammatory and oxidative stress for ameliorating intervertebral disc degeneration.  Science China-Materials,      [PMID:] [10.1007/s40843-024-3153-8]
22. Xianquan Feng, Lingjun Zeng, Lina Wu, Zhenzhen Chen, Wanjing Lin, Hongtao Song, Fenghua Lan.  (2024)  Self-delivery nanodrug to manipulate tumor microenvironment for boosting photodynamic cancer immunotherapy.  BIOMEDICINE & PHARMACOTHERAPY,      [PMID:39094543] [10.1016/j.biopha.2024.117220]
23. Cuiping Long, Qian Zhou, Min Xu, Xin Ding, Xingxing Zhang, Ya Zhang, Yuping Tang, Guangguo Tan.  (2024)  Sini Decoction alleviates inflammation injury after myocardial infarction through regulating arachidonic acid metabolism.  Chinese Herbal Medicines,      [PMID:39949807] [10.1016/j.chmed.2023.12.004]
24. Wenqing Sun, Yufeng Xu, Zhiqin Liu, Wei Liu, Hongting Wang, Guanyu Chang, Zihui Yang, Zhen Dong, Jianguo Zeng.  (2024)  Studies on pharmacokinetic properties and intestinal absorption mechanism of sanguinarine chloride: in vivo and in situ.  TOXICOLOGY MECHANISMS AND METHODS,      [PMID:39087424] [10.1080/15376516.2024.2383366]
25. Xianquan Feng, Yan Zhang, Wanjing Lin, Jing Li, Fei Wu, Qingyu Lu, Hongtao Song, Hao Zhang, Fenghua Lan, Jun Lu.  (2025)  A Self-Amplifying Photodynamic Biomedicine for Cascade Immune Activation Against Triple-Negative Breast Cancer.  Small,      [PMID:39846288] [10.1002/smll.202410214]
26. Yue Wang, Chen Wei, Xiaoyu Zhao, Fantao Lin, Shijie Liu, Jingkun Bai.  (2025)  A pH-sensitive peptide amphiphilic-based drug delivery system inhibits hepatocellular carcinoma growth by suppressing hepatic stellate cell activation.  Materials Today Bio,      [PMID:40453820] [10.1016/j.mtbio.2025.101821]
27. Xianbang Hou, Ran Chen, Juan Wu, Yujie Huang, Xueyuan Zhang, Shaobao Xu, Liwei He.  (2025)  Selective COX-2 inhibitors from natural sources: Insights from the analysis of components absorbed into blood from Isatidis Radix Lignans.  JOURNAL OF ETHNOPHARMACOLOGY,      [PMID:40354841] [10.1016/j.jep.2025.119930]
28. Wenling Zheng, Junni Ke, Kaerdun Liu, Rongrong Xue, Fenghua Chen.  (2025)  Aqueous Solution Spray Drying Preparations of Binary Amorphous Solid Dispersions.  Crystals,  15  (4): (323).  [PMID:] [10.3390/cryst15040323]
29. Minqian Luo, An Chen, Shiyu Shan, Minshan Guo, Ting Cai.  (2025)  Molar Ratio-Dependent Crystallization in Coamorphous Celecoxib–Carbamazepine Systems: The Interplay of Thermodynamics and Kinetics.  MOLECULAR PHARMACEUTICS,      [PMID:40360458] [10.1021/acs.molpharmaceut.5c00278]
30. Hong-Fu Zhao, Si-Yi Han, Lu Xiao, Bo-Kang Yu, Ning Xia, Ying-Hua Zhang.  (2025)  Ultrasound-assisted extraction of anti-inflammatory actives from corn silk (Zea mays L.): process optimization, machine learning screening, and interaction mechanisms.  ULTRASONICS SONOCHEMISTRY,      [PMID:40577999] [10.1016/j.ultsonch.2025.107420]
31. Xiaomin Su, Yang Wang, Xifeng Qin, Yaqiong Xiao, Boshu Ouyang, Lina Hu, Lin Kang, Ruizhe Xu, Ce Xu, Zanya Sun, Chenyu Sun, Huishu Guo, Zhiqing Pang, Shun Shen.  (2025)  HIFU-Driven Targeted Pyroptosis Therapy in Basal-Like Breast Cancer.  Advanced Science,      [PMID:40946176] [10.1002/advs.202503830]
32. Dong-Wei Shao, Tong Xie, Ya-Tao Wang.  (2025)  A pH-responsive injectable hydrogel that modulates the inflammatory microenvironment for the treatment of osteoarthritis.  INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,      [PMID:41176002] [10.1016/j.ijbiomac.2025.148686]
33. Xin Zhao, Shibin Han, Cheng Chen, Xiaoyi Lv, Jiahe Li, Chen Chen.  (2025)  Deep learning-assisted SERS platform for label-free detection of celecoxib in serum using ag@Pt@porous silicon Bragg mirror composite substrate.  SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY,      [PMID:41242102] [10.1016/j.saa.2025.127165]
34. Lei Yu, Bai Yaowei, Bai Xiatong, Sun Bo, Zhu Licheng, Wu Wenlong, Su Yang, Zhang Hongsen, Wang Yingliang, Zheng Chuansheng.  (2025)  COX-2/PGE2 axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation.  JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,  44  (1): (321).  [PMID:41408296] [10.1186/s13046-025-03582-6]
35. Zhiling Chen, Huiling Zhou, Jie Song, Ben Xu, Can Wang, Fengchun He, Guisen Zhang, Tao Zhuang.  (2026)  A new drug-drug co-amorphous system of imipramine and celecoxib with improved solubility and synergistic antinociceptive effects.  EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS,      [PMID:41519309] [10.1016/j.ejpb.2026.114988]
36. Shuang Wang, Tianwu Chen, Yong Li, Lei Zhang, Jing Wang, Changsheng Liu.  (2026)  Friction-Adaptive Hydrogel Coating for Mechanical-Immune Synergy in Ligament-to-Bone Integration.  BIOMATERIALS,      [PMID:41633300] [10.1016/j.biomaterials.2026.124003]
37. Aoyu Zhang, Shuying Li, Jie Qiao, Chuanqi Zhong, Zhiwen Zhang, Xiguang Ye, Jun Jin, Shiyan Shang, Song Wu, Qing Zhang, Gongxu Yang.  (2026)  Isopsoralen alleviates osteoarthritis by modulating the MAPK/NF-κB signaling pathway and regulating the structure of gut microbiota.  JOURNAL OF ETHNOPHARMACOLOGY,      [PMID:41628870] [10.1016/j.jep.2026.121257]
38. Qihui Wang, Xinlu Huangfu, Huan Ouyang, Jian Liang, Shengyuan Zhang, Hua Nie, Huang Zeng, Li Yang, Hao Fan, Junwei He.  (2026)  Targeted screening of phenylpropanoids from Dendropanax proteus for rheumatoid arthritis therapy and mechanistic insights.  BIOORGANIC CHEMISTRY,      [PMID:] [10.1016/j.bioorg.2026.109810]
Solution Calculators
Reviews

Customer Reviews

Need help choosing the grade?

Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.

View Moligand™ grade guide →

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.